Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels—A pilot study

• Published in: Allergy (Copenhagen) Vol. 73; no. 5; pp. 1003 - 1012
• Main Authors: Eckl‐Dorna, J., Fröschl, R., Lupinek, C., Kiss, R., Gattinger, P., Marth, K., Campana, R., Mittermann, I., Blatt, K., Valent, P., Selb, R., Mayer, A., Gangl, K., Steiner, I., Gamper, J., Perkmann, T., Zieglmayer, P., Gevaert, P., Valenta, R., Niederberger, V.
• Format: Journal Article
• Language: English
• Published: Denmark Blackwell Publishing Ltd 01.05.2018; John Wiley and Sons Inc
• Subjects: Administration, Intranasal; Adult; allergen; Allergens; Allergens - administration & dosage; Allergens - immunology; Allergies; Anti-Allergic Agents - administration & dosage; Antigens, Plant - administration & dosage; Antigens, Plant - immunology; Bet v 1 antigen; CD40 antigen; Double-Blind Method; Female; half‐life; Humans; IgE; Immunoglobulin E; Immunoglobulin E - analysis; Immunoglobulin E - immunology; Immunoglobulin G; Immunotherapy; Intranasal administration; intranasal challenge; Male; Monoclonal antibodies; Nose; omalizumab; Omalizumab - administration & dosage; Original; ORIGINAL ARTICLES; Patients; Pilot Projects; Pollen; Rhinitis, Allergic, Seasonal - immunology; Young Adult; allergen; omalizumab; intranasal challenge; half-life; IgE

Background Administration of the therapeutic anti‐IgE antibody omalizumab to patients induces strong increases in IgE antibody levels. Objective To investigate the effect of intranasal administration of major birch pollen allergen Bet v 1, omalizumab or placebo on the levels of total and allergen‐sp...